Carroll Financial Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $1.26M | Buy |
22,666
+340
| +2% | +$18.4K | 0.07% | 161 |
|
|
2021
Q3 | $1.07M | Buy |
22,326
+76
| +0.3% | +$3.67K | 0.06% | 179 |
|
|
2021
Q2 | $932K | Sell |
22,250
-110
| -0.5% | -$4.26K | 0.05% | 184 |
|
|
2021
Q1 | $753K | Hold |
22,360
| – | – | 0.05% | 200 |
|
|
2020
Q4 | $780K | Hold |
22,360
| – | – | 0.05% | 184 |
|
|
2020
Q3 | $776K | Buy |
22,360
+76
| +0.3% | +$2.53K | 0.06% | 168 |
|
|
2020
Q2 | $729K | Buy |
22,284
+612
| +3% | +$19.5K | 0.06% | 172 |
|
|
2020
Q1 | $652K | Hold |
21,672
| – | – | 0.06% | 169 |
|
|
2019
Q4 | $627K | Sell |
21,672
-1,206
| -5% | -$33.4K | 0.05% | 196 |
|
|
2019
Q3 | $591K | Sell |
22,878
-732
| -3% | -$18.5K | 0.05% | 191 |
|
|
2019
Q2 | $602K | Buy |
23,610
+738
| +3% | +$18.2K | 0.05% | 188 |
|
|
2019
Q1 | $598K | Buy |
22,872
+19,392
| +557% | +$477K | 0.06% | 172 |
|
|
2018
Q4 | $82K | Hold |
3,480
| – | – | 0.01% | 413 |
|
|
2018
Q3 | $82K | Buy |
3,480
+4
| +0.1% | +$98 | 0.01% | 434 |
|
|
2018
Q2 | $80K | Buy |
3,476
+442
| +15% | +$10.5K | 0.01% | 428 |
|
|
2018
Q1 | $74K | Buy |
3,034
+1,000
| +49% | +$26.3K | 0.01% | 431 |
|
|
2017
Q4 | $54K | Buy |
2,034
+286
| +16% | +$7.27K | 0.01% | 470 |
|
|
2017
Q3 | $42K | Buy |
1,748
+4
| +0.2% | +$90 | ﹤0.01% | 526 |
|
|
2017
Q2 | $37K | Buy |
1,744
+4
| +0.2% | +$81 | ﹤0.01% | 552 |
|
|
2017
Q1 | $29K | Hold |
1,740
| – | – | ﹤0.01% | 586 |
|
|
2016
Q4 | $31K | Hold |
1,740
| – | – | ﹤0.01% | 547 |
|
|
2016
Q3 | $36K | Sell |
1,740
-48
| -3% | -$1.19K | 0.01% | 527 |
|
|
2016
Q2 | $48K | Buy |
1,788
+1,100
| +160% | +$30.2K | 0.01% | 452 |
|
|
2016
Q1 | $18K | Sell |
688
-442
| -39% | -$11.8K | ﹤0.01% | 634 |
|
|
2015
Q4 | $32K | Sell |
1,130
-520
| -32% | -$14.4K | 0.01% | 477 |
|
|
2015
Q3 | $44K | Sell |
1,650
-260
| -14% | -$7.36K | 0.01% | 420 |
|
|
2015
Q2 | $52K | Buy |
1,910
+1,356
| +245% | +$38.1K | 0.01% | 365 |
|
|
2015
Q1 | $15K | Buy |
554
+54
| +11% | +$1.24K | 0.01% | 469 |
|
|
2014
Q4 | $11K | Sell |
500
-190
| -28% | -$4.24K | 0.01% | 473 |
|
|
2014
Q3 | $15K | Buy |
690
+440
| +176% | +$10.1K | ﹤0.01% | 501 |
|
|
2014
Q2 | $6K | Hold |
250
| – | – | ﹤0.01% | 682 |
|
|
2014
Q1 | $6K | Hold |
250
| – | – | ﹤0.01% | 625 |
|
|
2013
Q4 | $4K | Hold |
250
| – | – | ﹤0.01% | 645 |
|
|
2013
Q3 | $4K | Buy |
+250
| New | +$4.21K | ﹤0.01% | 635 |
|
Other funds holding NVO
F
Carroll Financial Associates's NVO Position: Q4 2021 in Review
Carroll Financial Associates increased its Novo Nordisk (NVO) stake by 1.5% in Q4 2021, buying an estimated $18.4K and bringing the position to 22,666 shares worth $1.26M. The position accounts for 0.07% of the portfolio, ranked #161.
Carroll Financial Associates first reported a position in NVO in Q3 2013 and has held it in 34 quarters since. 886 funds tracked by Wall St. Rank hold NVO as of Q4 2021.
- Carroll Financial Associates held 22,666 shares of Novo Nordisk worth $1.26M as of Q4 2021.
- Carroll Financial Associates bought 340 Novo Nordisk shares in Q4 2021, an estimated $18.4K.
- Novo Nordisk made up 0.07% of Carroll Financial Associates's portfolio in Q4 2021, its #161 holding.
- Carroll Financial Associates first reported a position in Novo Nordisk in Q3 2013 and has held it in 34 quarters since.
- 886 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.